EPARs - Plavix/Clopidogrel hydrogen sulphate

EPARs for authorised medicinal products for human use - Plavix

FICHA FARMACOLÓGICA de Clopidogrel hydrogen sulphate. Contiene la Monografía en distintos idiomas (de la Comunidad Económica Europea), así como la discusión científica que sustenta su aprobación terapéutica. Para acceder a la monografía en idioma español, hacer doble clik en la sigla (es) en la fila que se sitúa más abajo del centro de la página oficial. Cerasale. Febrero 2009.

Active Substance
Clopidogrel hydrogen sulphate
International Nonproprietary Name or Common Name
Clopidogrel
Pharmaco-therapeutic Group
Platelet aggregation inhibitors excl. Heparin
ATC Code
BO1 A C04
Therapeutic Indication
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
• Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease
• Patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), in combination with acetylsalicylic acid (ASA)
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy